Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2666 results

Media Release / May 29, 2020
Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast cancer patients whose tumors harbor a PIK3CA mutation in Europe Phase III…
Media Release / May 28, 2020
Novartis data highlight benefit of early treatment initiation in patients with secondary progressive multiple sclerosis (SPMS)
Novartis presented a total of 34 abstracts at the Congress of the European Academy of Neurology (EAN), emphasizing its strong multiple sclerosis (MS) portfolio with 20 abstractsLong-term efficacy…
Media Release / Jun 02, 2020
Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Basel, June 2, 2020 — Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency has extended its review of the Supplemental Biologics…
Media Release / May 29, 2020
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years1 Study conclusions are drawn from the largest dataset and…
Media Release / Jun 05, 2020
Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving…
Media Release / Jun 04, 2020
Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis
Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 521 nr-axSpA…
Media Release / Jun 11, 2020
US FDA approves updated Novartis Beovu® label, to include additional safety information
Novartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients1 The…
Key Release / Jun 17, 2020
Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
FDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial…
Media Release / Jun 18, 2020
Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania
New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care Program continues progress in Ghana with more than 2000 patients…
Media Release / Jun 24, 2020
Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
83% of technology (tech) professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago 86% of tech professionals agree: the…